Hikma introduces daunorubicin HCl injection
Hikma Pharmaceuticals has launched daunorubicin HCl injection in 20 mg/4 ml and 50 mg/10 ml dosage strengths.
Hikma’s daunorubicin HCl injection is indicated in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia — myelogenous, monocytic, erythroid — of adults and for remission induction in acute lymphocytic leukemia of children and adults.
The product’s market value was approximately $9 million in the 12 months ended May 2018, according to IQVIA.
Hikma’s daunorubicin HCl injection is indicated in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia — myelogenous, monocytic, erythroid — of adults and for remission induction in acute lymphocytic leukemia of children and adults.
The product’s market value was approximately $9 million in the 12 months ended May 2018, according to IQVIA.